Nan Fung Trinity HK Ltd. Makes New Investment in Vor Biopharma Inc. $VOR

Nan Fung Trinity HK Ltd. purchased a new stake in shares of Vor Biopharma Inc. (NASDAQ:VOR) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 721,550 shares of the company’s stock, valued at approximately $13,767,000. Nan Fung Trinity HK Ltd. owned 1.17% of Vor Biopharma at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of VOR. Parallel Advisors LLC grew its holdings in shares of Vor Biopharma by 29,640.0% in the third quarter. Parallel Advisors LLC now owns 1,487 shares of the company’s stock worth $28,000 after acquiring an additional 1,482 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Vor Biopharma by 25.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,795 shares of the company’s stock valued at $198,000 after acquiring an additional 2,171 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Vor Biopharma in the third quarter valued at about $58,000. Fulcrum Asset Management LLP bought a new position in Vor Biopharma in the third quarter valued at about $64,000. Finally, Engineers Gate Manager LP lifted its holdings in Vor Biopharma by 37.5% in the second quarter. Engineers Gate Manager LP now owns 36,951 shares of the company’s stock valued at $680,000 after acquiring an additional 10,071 shares during the period. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. Weiss Ratings raised shares of Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 14th. Citigroup raised shares of Vor Biopharma to a “strong-buy” rating in a research report on Thursday, October 15th. Wedbush increased their price objective on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 12th. Finally, William Blair began coverage on shares of Vor Biopharma in a report on Wednesday, October 21st. They issued an “outperform” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Vor Biopharma presently has an average rating of “Buy” and an average price target of $38.29.

Vor Biopharma Stock Down 3.8%

Shares of NASDAQ:VOR opened at $19.32 on Friday. Vor Biopharma Inc. has a 1-year low of $6.50 and a 1-year high of $26.00. The firm’s 50 day simple moving average is $20.09 and its two-hundred day simple moving average is $17.50.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Friday, October 30th. The company reported ($1.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.64). On average, sell-side analysts anticipate that Vor Biopharma Inc. will post -2.74 EPS for the current fiscal year.

About Vor Biopharma

Vor Biopharma is a clinical-stage biotechnology company focused on developing cell therapies for blood cancers. The company combines gene editing of blood stem cells with engineered immune-cell therapies, with the goal of enabling targeted treatment while protecting healthy blood-forming cells. Its research has included trem-cel, an investigational gene-edited stem cell therapy designed to remove the CD33 protein from transplanted cells, and VCAR33, an investigational CAR T-cell therapy targeting CD33.